Achilles Therapeutics plc (NASDAQ:ACHL – Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 8,400 shares, a decrease of 56.3% from the July 31st total of 19,200 shares. Based on an average daily volume of 51,600 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company’s shares are short sold.
Achilles Therapeutics Stock Performance
Shares of ACHL stock opened at $0.74 on Friday. Achilles Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.76. The firm has a market cap of $30.26 million, a P/E ratio of -0.46 and a beta of 1.32. The business’s 50 day moving average price is $0.80 and its 200-day moving average price is $0.94.
Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.41) EPS for the quarter, hitting analysts’ consensus estimates of ($0.41). As a group, equities analysts predict that Achilles Therapeutics will post -1.26 EPS for the current year.
Institutional Investors Weigh In On Achilles Therapeutics
Achilles Therapeutics Company Profile
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Read More
- Five stocks we like better than Achilles Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Options Trading – Understanding Strike Price
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.